These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8640681)

  • 1. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
    Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
    Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
    Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
    Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
    Vitolo U; Orsucci L; Bertini M; Cavallero G; Gallamini A; Ghio R; Levis A; Rota-Scalabrini D; Resegotti L
    Haematologica; 1991; 76(1):43-6. PubMed ID: 2055560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
    Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
    Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
    Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):626-9. PubMed ID: 3827258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.